Farther Finance Advisors LLC Increases Stock Position in Hologic, Inc. $HOLX

Farther Finance Advisors LLC boosted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 38.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,538 shares of the medical equipment provider’s stock after buying an additional 703 shares during the quarter. Farther Finance Advisors LLC’s holdings in Hologic were worth $165,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in HOLX. United Services Automobile Association acquired a new position in shares of Hologic in the 1st quarter valued at $347,000. SG Americas Securities LLC boosted its position in shares of Hologic by 116.6% during the 1st quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider’s stock worth $594,000 after purchasing an additional 5,172 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Hologic during the 1st quarter worth $641,000. Cambridge Investment Research Advisors Inc. raised its stake in shares of Hologic by 1.7% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 32,056 shares of the medical equipment provider’s stock worth $1,980,000 after buying an additional 528 shares during the last quarter. Finally, Strs Ohio acquired a new position in shares of Hologic during the 1st quarter worth $12,910,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Evercore ISI boosted their target price on shares of Hologic from $62.00 to $68.00 and gave the company an “in-line” rating in a research note on Tuesday, July 8th. Royal Bank Of Canada upgraded Hologic from a “sector perform” rating to an “outperform” rating and upped their price target for the stock from $72.00 to $87.00 in a report on Wednesday, August 6th. UBS Group upped their price target on Hologic from $65.00 to $70.00 and gave the stock a “neutral” rating in a report on Thursday, July 31st. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and increased their target price for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. Finally, Mizuho set a $75.00 price target on Hologic in a research report on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $79.38.

Hologic Trading Up 1.3%

Shares of HOLX stock opened at $67.91 on Friday. The stock has a 50-day simple moving average of $66.93 and a 200 day simple moving average of $63.04. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $15.10 billion, a P/E ratio of 28.18, a P/E/G ratio of 2.30 and a beta of 0.63. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.39.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the previous year, the company earned $1.06 EPS. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the business’s stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the transaction, the chief executive officer owned 1,234,624 shares in the company, valued at $82,682,769.28. The trade was a 10.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 1.88% of the company’s stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.